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Zinc-ﬁngerE7 is themajor oncoprotein of high-risk human papillomaviruses (HPV)which causes cervical cancer. To date E7
oncoproteins have not been investigated in cervical adenocarcinoma. In this study we generated a rabbit
monoclonal anti-HPV-16 E7 antibody, RabMab42-3, which recognizes a conformational epitope in the E7
carboxy-terminal zinc-ﬁnger resulting in a strong increase in the sensitivity for the detection of cell-associated
HPV-16 E7 protein relative to conventional polyclonal anti-HPV-16 E7 antibodies. Using RabMab42-3, we show
that the subcellular localization of endogenous HPV-16 E7 oncoprotein varies during the cell cycle in cervical
cancer cells.Moreover,wedemonstrate for theﬁrst time that theHPV-16E7oncoprotein is abundantly expressed
in cervical adenocarcinoma in situ and adenocarcinoma, suggesting an important role of HPV-16 E7 for the
development of these tumors. Our ﬁndings suggest that the HPV-16 E7 oncoprotein could be a useful marker for
the detection of cervical adenocarcinoma and their precursors.g Research, Rennweg 10, 6020
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Persistent infections byhumanpapillomaviruses (HPV) are themain
etiologic factor for the development of cervical cancer, the secondmost
frequent gynecological cancer worldwide (reviewed in zur Hausen,
2002). Approximately 85% of cervical cancers are squamous cell
carcinomas (SCCs), whereas 15% are adenocarcinomas (ACs) (Vizcaino
et al., 1998; Pirog et al., 2000; Munoz et al., 2003). About 40 HPV
genotypes that can infect epithelial squamous and glandular cells in the
cervical mucosa have been described (de Villiers et al., 2004). On the
basis of epidemiological and biochemical data, these viruses are
classiﬁed as high-risk HPVs associated with intraepithelial lesions
with a high potential for progression to invasive carcinomaand low-risk
HPVs associated with benign hyperplasia (zur Hausen, 1991; Muñoz et
al., 1992, 2003; Bosch et al., 1995; Lacey et al., 2006). A subgroup of at
least 15 high-risk HPVs is associatedwith cervical intraepithelial lesionswith high potential for progression to carcinoma (Walboomers et al.,
1999; Muñoz et al., 2003). Infections by high-risk genotypes are
detected in virtually all cervical cancers (Bosch et al., 1995; Liaw et al.,
1999; Wallin et al., 1999; Walboomers et al., 1999). HPV-16 is the
predominant genotype worldwide in SCCs as well as in ACs with a
prevalence of approximately 55% in SCCs and50–70% inACs (Pirog et al.,
2000; Riethdorf et al., 2002; Muñoz et al., 2003).
Inactivation of cellular control functions in early cervical carcino-
genesis permits deregulated transcription of the HPV genes E6 and E7,
resulting in an overexpression of E6 and E7 (Dürst et al., 1985; Schwarz
et al., 1985; Romanczuk and Howley, 1992; Stoler et al., 1992; Jeon and
Lambert, 1995; Ziegert et al., 2003). This is consistent with the observed
increase of the high-risk E7 oncoprotein levels during early steps of
carcinogenesis in cells of the cervical squamous epithelium (Fiedler
et al., 2004). Both oncoproteins cooperate to trigger reprogramming of
cell proliferation, apoptosis, differentiation and metabolism and to
induce epigenetic reorganization and genomic instability (reviewed in
Zwerschke and Jansen-Dürr, 2000; McLaughlin-Drubin and Münger,
2009). Accordingly, E7, in cooperation with E6, can efﬁciently
immortalize human keratinocytes (Münger et al., 1989; Hawley-Nelson
et al., 1989; Hudson et al., 1990); and the consistent overexpression of
these two oncogenes is required to induce and to maintain the
55K. Dreier et al. / Virology 409 (2011) 54–68transformed phenotype of cervical cancer cells (reviewed in Münger
and Howley, 2002). E7 is the major HPV oncoprotein and its expression
is sufﬁcient to immortalize primary human epithelial cells at a low
frequency (Halbert et al., 1991; Reznikoff et al., 1994;Wazer et al., 1995)
and to induce cervical cancers in transgenicmice treatedwith lowdoses
of estrogens (Riley et al., 2003). Work of the last two decades has
demonstrated that E7 is an integral part of different cellular protein
complexes in the cytoplasm as well as in the nucleus and that E7 has
multiple biochemical functions in the deregulation of pathways
necessary for the oncogenic potential of the virus (reviewed in
Zwerschke and Jansen-Dürr, 2000; Narisawa-Saito and Kiyono, 2007;
McLaughlin-Drubin andMünger, 2009;Ghittoni et al., 2010;Moody and
Laimins, 2010; Pim and Banks, 2010).Fig. 1. RabMab42-3 detects a conformational epitope in the HPV-16 E7 protein. (A) Model o
(Ohlenschläger et al., 2006) and the alignment of E7 sequences of HPV-45 and -16 (Morande
the β1β2α1α2 secondary structure are shown. The side chains of the four cysteines (C58, C61
connecting β1 and β2 and in the C-terminal α2-helix are indicated. The epitope 86TLGIVCPI
in red. Moreover, the localization of the C-terminal mutations Δ52YNIVT56, Δ65LRL67,Δ75D
the mutations H2P and C24G are not indicated. (Lower panel) Amino acid sequence of the H
epitope recognized by RabMab42-3 is framed by the red box. (B) RabMab42-3 epitope mapp
RabMab42-3 and unrelated rabbit antibodies followed by a ﬂuorescently labeled secondary
RabMab42-3, two unrelated rabbit antibodies and “only secondary antibodies” are shown
proteins were separated by SDS PAGE and the E7 proteins detected by Western blotting us
expression vector for HPV-16 E7 or empty vector and the cervical cancer cell lines CaSki (H
onto the same PVDF membrane. The HPV-16 E7 protein was detected by Western blotting us
anti-HPV-16 E7 antibodies (right panel). (E) U-2 OS cells transiently transfected with an H
either with 200 pg/μl RabMab42-3 or 200 pg/μl afﬁnity-puriﬁed polyclonal anti-HPV-16 E7
labeled secondary antibodies. (F) Lysates of U-2 OS cells transiently expressing HPV-16 E7
protein was detected byWestern blotting using 0.625 μg/ml afﬁnity-puriﬁed polyclonal anti-
mutants as indicated were stained in indirect immunoﬂuorescence experiments with 2 ng/μ
(H) U-2 OS cells transiently expressing HPV-16 E7 wild type and mutants as indicated we
polyclonal anti-HPV-16 E7 antibodies followed by application of AlexaFluor488-labeled secThe incidence of cervical ACs is increasing (Peters et al., 1986;
Schwartz andWeiss, 1986; Chilvers et al., 1987; Eide, 1987; Zheng et al.,
1996; Vizcainoet al., 1998;Altekruse et al., 2003;Wanget al., 2004; Bray
et al., 2005). This disease is often at a more advanced stage when
detected resulting in worse curability and survival (Shingleton et al.,
1995). Moreover, adenocarcinoma in situ (ACIS) progress faster to
cervical glandular carcinoma compared to high grade squamous
intraepithelial lesions (Plaxe and Saltzstein, 1999), suggesting that
improved cervical cancer screeningprocedures are particularly required
for better detection of ACs and ACIS.Whereas high-risk HPV E7 proteins
are regularly expressed in SCCs (Fiedler et al., 2004; Ressler et al., 2007),
the levels of high-risk E7 oncoprotein in cervical ACs and their
precursors are unknown. Therefore we set out to analyze the E7f the structure of the HPV-16 E7 protein deduced from the NMR structure of HPV-45 E7
ll et al., 2008, see also Fig. 3B). (Upper panel) The carboxyl-terminal domains containing
, C91, C94) in the two CXXCmotifs coordinating the zinc ion (brown) located in the turn
CSQK97 in the carboxyl-terminal E7 zinc-ﬁnger recognized by RabMab42-3 is indicated
IR77,Δ79LEDLL83, C58G and C91G are indicated. Note the unstructured N-terminus and
PV-16 E7 protein. The sequences selected for mutations are indicated in yellow and the
ing: HPV-16 E7 peptides (see Table 1) were spotted on microarrays and incubated with
antibody (anti-rabbit-Cy5). The results of the HPV 16 E7 antigen peptide arrays with
. (C) Ten nanograms of puriﬁed recombinant HPV-16 E7, HPV-18 E7 and HPV-45 E7
ing 15 μg/ml RabMab42-3. (D) Lysates of U-2 OS cells transiently transfected with an
PV-16 positive) and HeLa (HPV-18 positive) were separated by SDS PAGE and blotted
ing either 15 μg/ml RabMab42-3 (left panel) or 0.625 μg/ml afﬁnity-puriﬁed polyclonal
PV-16 E7 expression vector were stained in indirect immunoﬂuorescence experiments
antibodies (positive control), as indicated, followed by application of AlexaFluor488-
wild type and mutants as indicated were separated by SDS PAGE and the HPV-16 E7
HPV-16 E7 antibodies. (G) U-2 OS cells transiently expressing HPV-16 E7 wild type and
l RabMab42-3 followed by application of AlexaFluor488-labeled secondary antibodies.
re stained in indirect immunoﬂuorescence experiments with 2 ng/μl afﬁnity-puriﬁed
ondary antibodies.
Fig. 1 (continued).
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HPV E7 oncoprotein is an adequate marker for the detection of cervical
AC and ACIS, using a novel rabbit monoclonal anti-HPV-16 E7 antibody.
Results
Detection of the HPV-16 E7 oncoprotein in cervical cancer cells
Structural analysis showed that the N-terminal part of E7 is
intrinsically unstructured, whereas the C-terminal domain forms a
highly structured zinc-ﬁnger loop (Liu et al., 2006; Ohlenschläger et
al., 2006; Fig. 1A). We immunized rabbits with puriﬁed native HPV-16
E7 protein (Fiedler et al., 2006) and screened the derived hybridomas
for suitable antibodies. Epitope mapping using microarrays with HPV-
16 E7 derived synthetic peptides (Fig. 1B and Table 1) identiﬁed one
rabbit monoclonal anti-HPV-16 E7 antibody, RabMab42-3, which
detected a speciﬁc epitope (86TLGIVCPICSQK97) in the carboxyl-
terminal domain of E7 containing two of the cysteine residues known
as key structuring elements of the E7 zinc-ﬁnger (Fig. 1A). Although
conformation-speciﬁc antibodies as a rule hardly work in peptide
microarray-based epitope mapping assays (Harlow and Lane, 1998),
data presented here suggests that the RabMab42-3-epitope is most
likely present in a rigid—the zinc ion comprising—structure in the
native protein. In keeping with our assignment as a conformation-
speciﬁc antibody, RabMab42-3 had relatively low afﬁnity to HPV-16
E7 in Western blot experiments where the protein was denatured by
SDS. Although RabMab42-3, when used in concentrations of 15 μg/ml
for Western blotting, recognized 10 ng of puriﬁed HPV-16 E7 protein
(Fig. 1C) as well as HPV-16 E7 protein in lysates of HPV-16 E7
expressing cells (Fig. 1D), our afﬁnity-puriﬁed rabbit polyclonal anti-
HPV-16 E7 antibodies (Fiedler et al., 2004) recognized the denatured
HPV-16 E7 protein much better even when used at much (N25fold)
lower concentration (Fig. 1D). In contrast, RabMab42-3 had a high
afﬁnity to native cell-associated HPV-16 E7 protein upon detection by
indirect immunoﬂuorescence. U-2OS cells transiently expressing
HPV-16 E7 were stained with RabMab42-3 (Fig. 1E, upper and middle
panel), and viewed using a confocal laser-scanning microscope. In the
vast majority of the transiently transfected cells both cytoplasmic and
nuclear HPV-16 E7 staining was detected (Fig. 1E, upper panel), while
in a small number of the transiently transfected cells E7 was
predominantly localized in the cytoplasm (Fig. 1E, middle panel).The signal generated by the afﬁnity-puriﬁed rabbit polyclonal anti-
HPV-16 E7 antibodies, when used in the same concentration, was less
intense (Fig. 1E). To further investigate the speciﬁcity of RabMab42-3,
U-2 OS cells were transiently transfected with expression vectors for
HPV-16 E7 mutants addressing the unstructured N-terminus as well
as the major structure determining elements in the C-terminal
domain (Fig. 1A). Western blot analysis using polyclonal antibodies
showed that the protein levels of all E7 mutants were either similar or
higher as the level of the HPV-16 E7 wild type protein (Fig. 1F). In
the immunoﬂuorescence assays RabMab42-3 detected the two N-
terminal E7 mutants, H2P and C24G, as well as carboxyl-terminal
mutants containing deletions in β1-sheet (Δ52YNIVT56), β2-sheet
(Δ65LRL67), and helix α1 (Δ75DIR77 and Δ79LEDLL83) (Fig. 1G).
However, RabMab42-3 could neither detect HPV-16 E7 C91G nor
C58G which both contain single point mutations in the zinc
coordination site. As expected from these results, the zinc-ﬁnger
double cysteine mutant HPV-16 E7 C58G/C91G was also not
detectable by RabMab42-3. This mutational analysis indicates that
the intact zinc-ﬁnger structure, which is coordinated by the two CXXC
motifs and the zinc ion (Liu et al., 2006; Ohlenschläger et al., 2006; see
also above Fig. 1A), is necessary for an efﬁcient recognition of the
HPV-16 E7 protein by RabMab42-3. In contrast, the afﬁnity-puriﬁed
rabbit polyclonal anti-HPV-16 E7 antibodies could readily detect all
HPV-16 E7 mutants, including the CXXC mutants, in U-2 OS cells by
immunoﬂuorescence analysis (Fig. 1H). Thus our mutational analysis
indicates that RabMab42-3 speciﬁcally recognizes the epitope
86TLGIVCPICSQK97 and suggests that the binding of the monoclonal
antibody depends on the intact conformation of the HPV-16 E7 zinc-
ﬁnger.
Next RabMab42-3 was employed for immunoﬂuorescence based
detection of endogenous E7 protein in cervical cancer cells. We found
that RabMab42-3 strongly detected the E7 protein in the HPV-16
positive CaSki cells by immunoﬂuorescence (Fig. 2A, panels 1–6). In
contrast, no signal was observed in HPV-18 positive HeLa, HPV-45
positive MS 751 cervical cancer cells and in unrelated U-2OS
osteosarcoma cells (Fig. 2A, panels 7–9). Moreover, RabMab42-3 did
not cross react with HPV-18 E7 and HPV-45 E7 proteins transiently
overexpressed in U-2 OS cells (Fig. 2A, panels 10–11) despite the fact
that both oncoproteins were strongly expressed in the U-2 OS cells, as
demonstrated in Western blot experiments using afﬁnity-puriﬁed
polyclonal anti-HPV-18 E7 and anti-HPV-45 E7 antibodies (Fig. 2B).
Fig. 1 (continued).
57K. Dreier et al. / Virology 409 (2011) 54–68Finally, the staining by RabMab42-3 could be blocked by preincuba-
tion of the monoclonal antibody with puriﬁed HPV-16 E7 antigen
(Fig. 2C). These results establish the speciﬁcity of RabMab42-3.
Confocal microscopy analysis demonstrated E7 microstructures
localized in both the cytoplasmic and nuclear compartments of
CaSki cells. While many of the cells in interphase showed a
predominantly diffuse cytoplasmic E7-staining with a ring structure
surrounding the nucleus and faint nuclear E7microstructures (Fig. 2A,
arrows in panels 1 and 6), some of these cells (~1%) showed a strong
nuclear E7 staining (Fig. 2A, arrowheads in panels 1 and 2, see also
below, Fig. 2E). A thorough analysis of U-2 OS cells transiently
overexpressing HPV-16 E7 demonstrated that most of the cells with
predominantly cytoplasmic HPV-16 E7 occurred shortly after cytoki-
nesis/G1 transition in the early G1 phase (Fig. 2D, upper and middle
panels), while the vast majority of the interphase cells had
predominantly nuclear E7 (Fig. 2D, lower panel). In CaSki cells
undergoing mitosis, RabMab42-3 stained various structures. One
conspicuous ﬁgure was formed by ligaments annulated around the
nucleus in prometaphase cells (Fig. 2A, arrowheads in panels 4 and 5).
In metaphase (Fig. 2A, arrows in panels 2, 3 and 5) and telophase cells
(Fig. 2A, arrowhead in panel 6) RabMab42-3 stained large structuresencompassing the chromosomes. These results demonstrate that the
subcellular localization of endogenous HPV-16 E7 oncoprotein varies
during the cell cycle. Strikingly, RabMab42-3 yielded high quality
immunoﬂuorescence E7 signals in CaSki cells at very low antibody
concentration (10 pg/μl), as compared to afﬁnity-puriﬁed rabbit
polyclonal anti-HPV-16 E7 antibodies (Fig. 2E), suggesting that the
sensitivity of RabMab42-3 is at least 20 times higher in immunoﬂu-
orescence experiments, with no apparent loss of speciﬁcity.
To more precisely characterize the performance of RabMab42-3
we established a direct ELISA using different amounts of randomly
coated recombinant HPV E7 protein and analyzed its reactivity against
HPV-16 E7, the E7 proteins of 10 other high-risk HPV genotypes and
the 2 most common low risk viruses, HPV-6 and HPV-11. As shown in
Fig. 3A, 2.5 ng HPV-16 E7 protein was readily detected using this
assay. However no cross reactivity was found against the E7 proteins
of the other HPV types. As expected, at higher antibody/antigen ratio a
moderate cross reactivity was detected against the E7 proteins of
HPV-33 and HPV-58 which belong to HPV species 9 (HPV-16 family)
and against the E7 proteins of HPV-6 and HPV-11. Almost no cross
reactivity was found against the E7 proteins of HPV species 7 (HPV-18,
-39, -45, -59). The alignment of the HPV E7 protein sequences
Fig. 1 (continued).
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downstream from the highly conserved 90VCPXC94 motif in the
epitope 86TLGIVCPICSQK97 provide the speciﬁc recognition of the
HPV-16 E7 protein by RabMab42-3. Note that the cross reactivity
analysis was conductedwith relatively high amounts of E7 proteins. In
an appropriate sandwich ELISA, RabMab42-3 detects ~500 fg of
recombinant HPV-16 E7 protein (Ehehalt et al., unpublished ﬁndings).
In keeping with these results RabMab42-3 showed also no cross
reactivity in immunoﬂuorescence experiments using U-2 OS cells
transiently overexpressing the corresponding HPV E7 proteins
(Fig. 2A and data not shown). Moreover, RabMab42-3 showed no
cross reactivity in peptide microarrays conducted with collections of
13mer peptides derived from the E7 proteins of the HPV genotypes
tested in Fig. 3.
Detection of the HPV-16 E7 oncoprotein in cervical AC and ACIS
Analysis of cervical ACs from 30 patients using GP5+/GP6+
primer PCR and HPV typing by EIA identiﬁed infections with different
HPV genotypes (Table 2). Twenty-six (87%) ACs were HPV-DNApositive, 14 (47%) contained mixed infections by two or more
genotypes, 23 (77%) were HPV-16 positive, 3 (10%) contained only
HPV-18 and in 4 ACs the HPV-type was apparently not detectable by
PCR. Among the 6 ACIS were 2 HPV-16 positive, 1 contained HPV-16/
58, 2 HPV-16/18 and others, and 1 HPV-18 (Table 3). As negative
controls, we used 22 cervical biopsies containing normal squamous
and glandular epithelia from hysterectomy specimens with multiple
leiomyomas and without cervical lesions, which were HPV-negative
in the PCR analysis (Ressler et al., 2007).
Like afﬁnity-puriﬁed polyclonal anti-HPV-16 E7 antibodies (Fiedler
et al., 2004; Ressler et al., 2007) RabMab42-3 recognized the HPV-16 E7
protein in parafﬁn sections of HPV-16 positive cervical SCCs and CIN IIIs
but generated no signal in HPV-negative normal cervical squamous
epithelia (Fig. 4). RabMab42-3 immunohistochemically detected the E7
oncoprotein in parafﬁn sections of all 23 HPV-16 positive ACs (Fig. 5A).
Almost all epithelial tumor cellswithin the tumor isletswere stainedbut
not the cells in adjacent connective tissues (Fig. 5B). A detailed analysis
showed variations in the E7 immunoreactivity across the individual
biopsies. Using an arbitrary scoring system, we classiﬁed the E7 protein
expression levels by semi-quantitative analysis in three categories
Table 1
Sequence of the HPV-16 E7 derived 13mer peptides used in the peptide microarrays.
HPV-16 E7 protein (peptide number) Amino acid position Sequence
1 1 MHGDTPTLHEYML
2 3 GDTPTLHEYMLDL
3 5 TPTLHEYMLDLQP
4 7 TLHEYMLDLQPET
5 9 HEYMLDLQPETTD
6 11 YMLDLQPETTDLY
7 13 LDLQPETTDLYSY
8 15 LQPETTDLYSYEQ
9 17 PETTDLYSYEQLN
10 19 TTDLYSYEQLNDS
11 21 DLYSYEQLNDSSE
12 23 YSYEQLNDSSEEE
13 25 YEQLNDSSEEEDE
14 27 QLNDSSEEEDEID
15 29 NDSSEEEDEIDGP
16 31 SSEEEDEIDGPAG
17 33 EEEDEIDGPAGQA
18 35 EDEIDGPAGQAEP
19 37 EIDGPAGQAEPDR
20 39 DGPAGQAEPDRAH
21 41 PAGQAEPDRAHYN
22 43 GQAEPDRAHYNIV
23 45 AEPDRAHYNIVTF
24 47 PDRAHYNIVTFSS
25 49 RAHYNIVTFSSKS
26 51 HYNIVTFSSKSDS
27 53 NIVTFSSKSDSTL
28 55 VTFSSKSDSTLRL
29 57 FSSKSDSTLRLSV
30 59 SKSDSTLRLSVQS
31 61 SDSTLRLSVQSTH
32 63 STLRLSVQSTHVD
33 65 LRLSVQSTHVDIR
34 67 LSVQSTHVDIRTL
35 69 VQSTHVDIRTLED
36 71 STHVDIRTLEDLL
37 73 HVDIRTLEDLLMG
38 75 DIRTLEDLLMGTL
39 77 RTLEDLLMGTLGI
40 79 LEDLLMGTLGIVS
41 81 DLLMGTLGIVSPI
42 83 LMGTLGIVSPISS
43 85 GTLGIVSPISSQK
44 86 TLGIVSPISSQKP
59K. Dreier et al. / Virology 409 (2011) 54–68(Fig. 5B): 3 ACs were classiﬁed as +3, 2 as +2 and 18 as +1. No E7
proteins were detected in normal cervical specimens, neither in
connective tissue and cervical glandular epithelia (Fig. 5B, right panel)
nor in cervical squamous epithelia (Fig. 4). Both glandular cells and
squamous epithelial cells in non-neoplastic areas of cancer biopsies
were not stained.
The cyclin-dependent kinase inhibitor p16INK4a is frequently
upregulated in HPV-positive cervical precancers and cancers (Klaes
et al., 2001; Tsoumpou et al., 2009). Although a few cervical cancers
are p16INK4a negative (Tsoumpou et al., 2009), some other tumors are
p16INK4a positive via non-HPV related mechanisms and p16INK4a was
detected in normal epithelia (Riethdorf et al., 2002; Ressler et al.,
2006), p16INK4a is applied as surrogate marker of high-risk or
integrated HPV infection in cervical specimens which could act as
an adjunct to current cytological and histological assessment of
cervical smears and biopsies. In our study all HPV-16 E7 positive ACs
stained positive by the anti-p16INK4a antibodies (Fig. 5C), underlining
that p16INK4a is frequently expressed in cervical ACs. The Ki-67
antibodies, which were employed as a control for proliferating cells
(Gore et al., 1995), stained the same tumor cell islets as RabMab42-3
and the anti-p16INK4a antibodies (Fig. 5D). In accordance with
previous studies approximately 50% of the tumor cells stained positive
for Ki-67.RabMab42-3 stained the 4 ACs in which HPV-DNA was undetect-
able by PCR analysis in our hands (Fig. 5E, left panel), suggesting that
these biopsies do contain HPV-16. These ﬁndings are underlined by
the positive anti-p16INK4a staining (Fig. 5E, right panel).
We analyzed whether the HPV-16 E7 oncoprotein is detectable in
ACIS. The dysplastic cells in the 5 HPV-16 positive ACIS stained
positive with RabMab42-3 (Fig. 6A). The intensity of the E7 staining in
the tumor cells of all ﬁve specimens were classiﬁed as strong (+3) by
semi-quantitative analysis using the same arbitrary scoring system as
for the ACs. This suggests that high HPV-16 E7 oncoprotein levels
correlate with ACIS and that the E7 levels in ACIS are sufﬁcient for
malignant progression. Similar to the results obtained by the
immunoﬂuorescence experiments with the HPV-16 positive CaSki
cells (Fig. 2A, C and E), the subcellular localization of E7 in most of the
tumor cells in the ACIS was predominantly cytoplasmic, whereas a
few cells had a predominantly nuclear E7 staining. Normal glandular
epithelial cells adjacent to dysplastic epithelial cells in a gland of the
same ACIS were not stained (Fig. 6A, right panel), and no staining was
observed in any cell type in HPV-DNA negative biopsies of normal
tissue (Fig. 6B). Anti-p16INK4a antibodies stained all tumor cells in the
ACIS (Fig. 6C, left panel) and the proliferation marker Ki-67 was
detected in 30–50% of the cells in the tumor islets (Fig. 6C, right
panel).
Discussion
High-risk HPV E7 oncoproteins have great potential as markers for
the detection of cervical precancers and cancers (Doorbar, 2007;
Ressler et al., 2007; zur Hausen, 2002). However, HPV E7 oncoproteins
are little investigated in cervical precancers and cancers in humans
due to the lack of antibodies sufﬁcient in speciﬁcity and sensitivity for
the detection of E7. In this study, we generated highly speciﬁc and
sensitive anti-HPV-16 E7 RabMabs and showed for the ﬁrst time that
the HPV-16 E7 oncoprotein is abundantly expressed in cervical ACs
and ACIS but not in normal glandular cervical epithelium. This
indicates the importance of the E7 oncoprotein for the development of
ACIS as well as progression to cervical AC. These data, together with
studies detecting E7 oncoproteins in cervical SCCs and high-grade
CINs (Fiedler et al., 2004, 2005; Ressler et al., 2007) suggest that E7
oncoproteins can be considered as markers for premalignant and
malignant cervical tumors.
The role of high-risk HPV E7 as oncoprotein in cervical carcino-
genesis is established (reviewed in McLaughlin-Drubin and Münger,
2009). However, earlier attempts to detect E7 oncoproteins in cervical
specimens were hampered by the fact that HPV E7 oncoproteins
display low immunogenicity. The recent description of a solution
structure for HPV E7 proteins indicates that the highly conserved N-
terminal part of E7 proteins is intrinsically unstructured (Liu et al.,
2006; Ohlenschläger et al., 2006), providing a potential explanation
for the low immunogenicity.Whereas E7 proteins contain a rigid zinc-
ﬁnger structure in the C-terminal domain, no antibodies were
described so far that would speciﬁcally recognize this domain. We
produced polyclonal anti-HPV-16 E7 antisera in both rabbits and
goats which are of sufﬁcient sensitivity and speciﬁcity to detect E7
proteins in cervical SCCs (Fiedler et al., 2004, 2005, 2006; Ressler et al.,
2007). These antisera recognize epitopes in both the N-terminal and
C-terminal part of E7 with varying afﬁnity (unpublished results). This
is probably due to the presence of antibodies of lower afﬁnity and/or
speciﬁcity recognizing linear epitopes in the N-terminus and
antibodies of higher afﬁnity and/or speciﬁcity recognizing epitopes
in the C-terminus of E7.While the lack of conformational diversity in a
rigid structure, such as the E7 zinc-ﬁnger, lowers the energy needed
for protein binding, it is conceivable that this leads to a high afﬁnity to
target proteins (Colas, 2000). This suggests that the afﬁnity of speciﬁc
monoclonal antibodies to the E7 zinc-ﬁnger might be higher than to
the unstructured E7 N-terminus. Such antibodies can be selected by
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Fig. 2. Detection of endogenous HPV-16 E7 protein in CaSki cells. (A) Cells were stained with RabMab42-3 as indicated, followed by application of AlexaFluor488-labeled secondary
antibodies. CaSki cells (panels 1–6). HeLa (panel 7), MS 751 (panel 8), U-2 OS (panel 9), U-2 OS/HPV-18 E7 (panel 10) and U-2 OS/HPV-45 E7 (panel 11) cells served as negative controls.
I=interphase, PM=prometaphase,M=metaphase, T=telophase. (B)U-2OS cells transiently expressingHPV-18E7 orHPV-45E7wild type as indicatedwere separated by SDSPAGE and
the E7 proteins detected by Western blotting using afﬁnity-puriﬁed polyclonal antibodies against HPV-18 E7 and HPV-45 E7 (Fiedler et al., 2005), respectively. (C) Immunoﬂuorescence
staining by RabMab42-3was blocked bypreincubation of the antibodywith puriﬁed immobilizedGST-HPV-16E7 antigen (1 μg/μl) butnot GSTprotein (1 μg/μl). (D)U-2OS cells transiently
overexpressingHPV-16E7were stained in indirect immunoﬂuorescence experimentswithRabMab42-3 followedby applicationofAlexaFluor488-labeled secondary antibodies. (Upper and
middle panel) HPV-16 E7 expressing cells shortly after cytokinesis/G1 transition are shown. (Lower panel) An interphase cell with predominantly nuclear HPV-16 E7 staining is shown.
(E)Comparisonof thesensitivity of RabMab42-3andafﬁnity-puriﬁed rabbitpolyclonalα-HPV-16E7antibodies for thedetectionof cell-associatedendogenousHPV-16E7protein in indirect
immunoﬂuorescence experiments. For the detection of E7 protein, HPV16-positive CaSki cells were stained with decreasing concentrations (200–10 pg/μl) of either RabMab42-3 (right
panel) or afﬁnity puriﬁed polyclonal α-HPV16-E7 antibodies (left panel), as indicated, followed by application of AlexaFluor488-labeled secondary antibodies.
61K. Dreier et al. / Virology 409 (2011) 54–68screening of the given hybridomas (Harlow and Lane, 1998). In fact,
when monoclonal anti-HPV-16 E7 antibodies were generated from
rabbits, one hybridoma (RabMab42-3) was derived that produced an
antibody against a C-terminal epitope of E7 within the C-terminal
zinc-ﬁnger structure. This epitope differs from the epitopes recog-
nized by our previously used polyclonal anti-HPV-16 E7 antibodies
(Fiedler et al., 2004; Ressler et al., 2007; unpublished results).Employing several independent techniques, epitope mapping using
peptide microarrays, Western blot analysis, mutational analysis of the
RabMab42-3/HPV-16 E7 interaction using immunoﬂuorescence
assays, ELISA, competition experiments with puriﬁed HPV-16 E7
protein and immunohistochemistry experiments using parafﬁn
embedded cervical cancer biopsies, we provided evidence that the
monoclonal rabbit anti-HPV-16 E7 antibody RabMab42-3 speciﬁcally
Fig. 2 (continued).
62 K. Dreier et al. / Virology 409 (2011) 54–68recognizes a conformational epitope (86TLGIVCPICSQK97) in the
carboxyl-terminal domain of the HPV-16 E7 protein containing half
of the zinc coordinating motif in its center (Fig. 1A). Of note, we
demonstrated that the rabbit polyclonal antiserum recognized theFig. 3. Speciﬁcity of RabMab42-3 in ELISA using randomly coated HPV E7 proteins. A) Direct
RabMab42-3 (14 ng/100 μl) is shown. B) Alignment of HPV E7 protein sequences that we
conservation. RabMab42-3 epitope is boxed in red.HPV-16 E7 mutants C58G, C91G and C58G/C91G, which contain point
mutations in the major structuring elements of the E7 zinc-ﬁnger, in
Western blot as well as immunoﬂuorescence experiments; however,
the HPV-16 E7 CXXC mutants were not recognized by RabMab42-3,ELISA using 2.5 and 10 ng of randomly coated E7 antigens as indicated and biotinylated
re used for ELISA in Fig. 2A. Color coding: deep to light blue: high to low sequence
Table 2
HPV-typing of 30 cervical adenocarcinomas (AC) by GP5+/6+ primer PCR and EIA.
HPV type AC
HPV-16 9 (30%)
HPV-18 3 (10%)
HPV-16, -18 8 (27%)
HPV-16, -18, -31 1 (3%)
HPV-16, -18, -58 3 (10%)
HPV-16, 58 2 (7%)
not detected 4 (13%)
Total 30 (100%)
Table 3
HPV-typing of six adenocarcinoma in situ (ACIS) by GP5+/6+ primer PCR and EIA.
HPV type ACIS
HPV-16 2 (33%)
HPV-16, -58 1 (17%)
HPV-16, -58, -18 1 (17%)
HPV-16, -58, -18, -33 1 (17%)
HPV-18 1 (17%)
Total 6 (100%)
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depends on the intact spatial structure of the HPV-16 E7 zinc-ﬁnger.
The speciﬁcity of RabMab42-3 is further underscored by the fact that
RabMab42-3 showed almost no cross reactivity against the E7
proteins of diverse HPV genotypes.
RabMab42-3 speciﬁcally detected endogenous E7 protein in CaSki
cells. In comparison to the E7 pattern recognized by afﬁnity-puriﬁed
polyclonal anti-HPV-16 E7 antibodies (Fiedler et al., 2004; Ressler
et al., 2007), the cytoplasmic as well as nuclear E7 structuresFig. 4. Detection of high-risk HPV E7 oncoproteins in cervical SCC and CIN III. (A and B) Detec
RabMab42-3 using an immunoperoxidase staining protocol. (C) Epithelium and connective t
(D) Detection of HPV-16 E7 protein in parafﬁn sections of a HPV-16 DNA positive CIN III by Ra
cervical squamous epithelium served as negative control.recognized by RabMab42-3 were less homogenously distributed
throughout the cells. It is likely that this result is due to the differences
in epitope-recognition between the given antibodies and to the
markedly higher sensitivity of RabMab42-3 in the immunoﬂuores-
cence experiments detecting the cell-associated native HPV-16 E7
protein. Nevertheless, both antibodies detected endogenous E7
protein in cytoplasmic as well as nuclear sites in CaSki cells (Fiedler
et al., 2004; Ressler et al., 2007; this study). The microstructures
stained by RabMab42-3 in the confocal laser-scanning microscopy
experiments (layer thickness≤1.3 micrometer) varied among the
individual cells in the CaSki population, which may reﬂect a
differential subcellular localization of E7 during the cell cycle. In
mitotic CaSki cells, RabMab42-3 detected structures resembling
components of the cytoskeleton and in part of the spindle apparatus.
This supports conclusions from previous studies showing a functional
interaction of E7 with centrosomes (Duensing et al., 2000; Nguyen
et al., 2007). However, the clariﬁcation of the cytoplasmic structures
stained by RabMab42-3 warrants further studies. A small subset of
interphase CaSki cells had a strong nuclear E7 staining, whereas others
showed faint E7 structures pervading the nucleus. It is likely that the
nuclear E7 structures reﬂect well established nuclear E7 functions,
such as deregulation of the p16Ink4A/pRb pathway (reviewed in Howley
et al., 1991; Zwerschke and Jansen-Dürr, 2000; zur Hausen, 2002;
Narisawa-Saito and Kiyono, 2007; McLaughlin-Drubin and Münger,
2009; Ghittoni et al., 2010; Moody and Laimins, 2010; Pim and Banks,
2010). In the vast majority of the interphase cells, RabMab42-3
produced predominantly cytoplasmic staining, probably reﬂecting the
well described cytoplasmic E7 functions (reviewed in Zwerschke and
Jansen-Dürr, 2000; McLaughlin-Drubin and Münger, 2009). Similar to
our results in CaSki cells, HPV-16 E7was detected in both the cytoplasm
and nucleus of the tumor cells in both ACIS and AC, whereby the
cytoplasmic localization of HPV E7 preponderated in all biopsies. These
data are in agreement with results previously demonstrated in cervical
SCCs and CINIIIs (Fiedler et al., 2004, 2005; Ressler et al., 2007). Thetion of HPV-16 E7 protein in parafﬁn sections of a HPV-16 DNA positive cervical SCC by
issue adjacent to tumor islets in the HPV-16 DNA positive cervical SCC shown in A and B.
bMab42-3 using an immunoperoxidase staining protocol. (E) HPV DNA negative normal
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Fig. 6. Detection of HPV E7 oncoproteins in cervical ACIS. (A) Detection of the HPV-16 E7 oncoprotein in three different mixed infected HPV 16/18 DNA positive ACIS using
RabMab42-3 (Magniﬁcation 400×). (B) No staining of normal cervical glandular epithelium and connective tissue from aHPV-DNA negative biopsy with the anti-HPV-16 E7 RabMab
(Magniﬁcation 400×). (C) Staining of a HPV-16/18 DNA-positive ACIS by anti-p16INK4a and anti-Ki-67 antibodies, as indicated (Magniﬁcation 400×).
65K. Dreier et al. / Virology 409 (2011) 54–68subcellular localizations of E7 found in the present study are in
agreement with biochemical, indirect immunoﬂuorescence, immuno-
histochemical and electron microscopy studies, conducted in cervical
cancer biopsies in situ, cervical cancer cell lines and experimental cells
transiently overexpressing E7, which have demonstrated that HPV-16
E7 is located in both the cytoplasm (Smotkin and Wettstein, 1987;
Zatsepina et al., 1997; Zwerschke et al., 2000; Fiedler et al., 2004; Huh et
al., 2005; Nguyen et al., 2007; Ressler et al., 2007) and the nucleus (Sato
et al., 1989;Greenﬁeld et al., 1991; Zatsepina et al., 1997; Smith-McCune
et al., 1999; Fiedler et al., 2004; Ressler et al., 2007). In keeping with
these ﬁndings it was shown that HPV-16 E7 can be actively transported
into the nucleus (Angeline et al., 2003), contains a nuclear export
sequence and can shuttle between the nucleus and cytoplasm (Knapp
et al., 2009).
All HPV DNA-positive cervical ACs and ACIS investigated were
either HPV-16 and/or HPV-18 positive and the 4 ACs in which the
HPV-type was not detectable in the parafﬁn embedded specimens by
PCR in our hands stained HPV-16 E7 protein as well as p16INK4a
positive, reﬂecting the high prevalence of HPV-16 and HPV-18 in
cervical AC (Pirog et al., 2000; Riethdorf et al., 2002). HPV-18 E7 could
also be detected in cervical ACs using RabMabs to HPV-18 E7 (data not
shown); however, available antibodies to HPV-18 E7 recognized
linear epitopes in the N-terminus of E7 and were therefore not
included in this study.
Using RabMab42-3, we detected high levels of HPV-16 E7
associated with ACs as well as ACIS relative to normal cervicalFig. 5. Detection of high-risk HPV E7 oncoproteins in cervical ACs. (A) Detection of HPV-16 E
RabMab42-3 using an immunoperoxidase staining protocol. HPV DNA negative normal cervica
panels) Immunoperoxidase stainings of parafﬁn sections fromdifferent lesions ofHPV-16DNAp
intensity in 3 categories was used. The strongest staining intensity was set 100% and the staini
(Right panel) Normal cervical glandular epithelium (NGE) from a HPV-DNA negative biopsy sta
ACs stained by anti-p16INK4a antibodies (Magniﬁcation 400×). (D) Histological sections of HP
biopsy in which HPV DNA could not be detected by PCR analysis, stained by RabMab42-3 andepithelium. Although larger studies are necessary, this initial work
suggests an important role of E7 in precancerous and cancerous
progression. In most of the ACs analyzed, the E7 protein levels were at
a similar level or lower as in ACIS, suggesting that the E7 levels in ACIS
are sufﬁcient for malignant progression. Tumor size, depth of
invasion, and grading of the invasive tumor front are main prognostic
factors in early cervical AC (El-Ghobashy et al., 2005). We compared
the E7 oncoprotein levels in the cervical AC with the histopathologic
staging and grading of these lesions according to the criteria deﬁned
by the tumor-node-metastasis system of the Union Internationale
Contre le Cancer (Sobin and Wittekind, 2002). However, whereas the
detection of the E7 oncoprotein always coincided with the presence of
an invasive cervical adenocarcinoma, there was no correlation
between the E7 protein levels and the pathologic prognostic variables
(tumor size, lymph node status, metastases at distance, or histologic
grading).
Our results are in agreement with the regular detection of HPV E7
oncoproteins in human cervical SCCs and high-grade CINs (Fiedler
et al., 2004, Fiedler et al., 2005; Ressler et al., 2007) as well as the high
oncogenic potential of high-risk HPV E7 in vitro and in animal models
(reviewed in Zwerschke and Jansen-Dürr, 2000; zur Hausen, 2002;
Narisawa-Saito and Kiyono, 2007; McLaughlin-Drubin and Münger,
2009; Ghittoni et al., 2010; Moody and Laimins, 2010; Pim and Banks,
2010). Together the data suggest that high-risk HPV E7 proteins could
be useful as speciﬁc markers for the detection of cervical cancers and
high-grade precancers of squamous and glandular origin.7 protein in parafﬁn sections of different lesions of HPV-16 DNA positive cervical ACs by
l glandular epithelium (NGE) served as negative control (Magniﬁcations 200×). (B) (Left
ositive ACswith RabMab42-3. An arbitrary scoring system to grade the E7 protein staining
ng intensity rated as follows: (+3) 71–100%+++; (+2) 41–70%++; (+1) 10–40% +.
inedwith RabMab42-3 (Magniﬁcation 400×). (C) Histological sections of HPV-16 positive
V-16 positive ACs stained by anti-Ki-67 antibodies (Magniﬁcation 400×). (E) Cervical AC
anti-p16Ink4a antibodies (Magniﬁcation 400×).
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Patients
Parafﬁn-embedded conization specimens from women with
cervical AC, ACIS, SSC, and CIN III were diagnosed according to the
WHO-classiﬁcation of tumors of female genital organs (Wells et al.,
2003) by the division of pathology and collected by the National
Tumour Registry of the National Health Laboratory, Luxembourg or by
the departments of Obstetrics and Gynecology, Medical University
Innsbruck, Austria. Twenty-two normal cervical squamous and
glandular epithelia were obtained from the division of Pathology,
National Health Laboratory, Luxembourg and the departments of
Obstetrics and Gynecology, Medical University Innsbruck, Austria
(Ressler et al., 2007).
HPV-typing
Preparation of HPV DNA and HPV typing was conducted as
described (Jacobs et al., 1997).
Generation and characterization of rabbit monoclonal anti-HPV-16 E7
antibodies
HPV-16 E7 protein was puriﬁed as described (Fiedler et al., 2006)
and used to generate rabbit monoclonal antibodies in collaboration
with Epitomics Inc., (Burlingame, CA, USA). Hybridome subclones
were characterized by ELISA, Western blot, and immunoﬂuorescence.
E7 epitopes were analyzed by JPT Peptide Technologies GmbH (Berlin,
Germany) using peptide microarrays. To do this, collections of HPV E7
derived 13mer peptides displayed on peptide microarrays were
incubated with RabMab42-3 and unrelated rabbit control antibodies.
The determination of peptide-antibody binding was performed by
RepliTope-analysis where the peptide microarray was incubated with
the primary antibody followed by a ﬂuorescently labeled secondary
antibody (anti-rabbit-Cy5). After washing the peptide microarrays
were dried using a microarray centrifuge and scanned in a high
resolution microarray scanning system with appropriate wavelength
settings.
Cell culture and transfection
The human cervical cancer cell lines CaSki (German Cancer
Research Center, Heidelberg, Germany), MS751 (Geisbill et al.,
1997) and HeLa (ATCC-LGC, Manassas, USA) and the human
osteosarcoma cell line U-2OS were cultured in DMEM plus 10% FCS
(Fiedler et al., 2004). Cells were transiently transfected using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). HPV-16 E7 wild type
and mutants were overexpressed using pJ4W plasmids (Massimi et
al., 1997; Mannhardt et al., 2000; Prathapam et al., 2001).
Western blot analysis
Western blot analysis was performed as described (Fiedler et al.,
2004).
Indirect immunoﬂuorescence experiments
Cells were ﬁxed with 4% (w/v) PFA/1× PBS, permeabilized with
0.1% (w/v) Na-Citrate/0.3% (v/v) Triton-X-100, blocked with 1× PBS/
1%BSA and incubated for 1 h at 37 °C with anti-HPV-16 E7 antibodies
in 1× PBS/1%BSA. After washing in 1× PBS and staining with
secondary IgGs (DAKOCytomation, Hamburg), cells were processed
for indirect immunoﬂuorescence microscopy and viewed using a
confocal laser-scanning system (Mannhardt et al., 2000).Immunohistochemical detection of HPV-16 E7, Ki-67 and p16INK4a
Parafﬁn-embedded tissue-sections (2 μM) were deparafﬁnized in
xylene and incubated for 5 min each in 100%, 90%, 80%, 70% and 50%
isopropanol. Probes were cooked in a steamer, 30 min in 10 mM
Citrate buffer pH 6.0 for p16INK4a and Ki-67 staining or 1 h in DAKO
retrieval solution pH 6.1 (S1700) for HPV E7 staining. Peroxidase
was blocked with 20% H2O2 for 15 min. Note since RabMab42-3 is
a conformation-speciﬁc antibody the initial ﬁxing of the tissues
and the antigen retrieval procedure is critical. After washing in H2O
the samples were blocked for 15 min in serum (goat serum for
RabMab42-3 and anti-Ki-67 antibody staining; rabbit serum for anti-
p16INK4a antibody staining) diluted 1:10 in TBS/BSA (TBS=7.75 g
Tris–HCl pH 7.5, 8.78 g NaCl ad 1 l H2O; TBS/BSA=5% BSA in TBS). The
sections were then incubated for 1 h at RT in TBS/BSA either with
biotinylated anti-HPV-16 E7 RabMab42-3 (100–250 ng/μl), anti-
p16INK4a (Neomarkers, Vienna) or anti-Ki-67 antibodies (Neomar-
kers). After washing in TBS/0.1% (v/v) Tween 20 bound antibodies
were detected with biotin/streptavidin peroxidase conjugates, visu-
alized with DAB solution, counterstained with Hemalaun, dehydrated
and mounted as described (Ressler et al., 2007).
ELISA procedure
Wells of microtiter plates (Maxisorp F, Nunc, Vienna) were coated
overnight (4 °C) with different amounts of recombinant bacterial
produced untagged HPV E7 proteins (Fiedler et al., 2006) in 100 μl of
coating buffer (0.1 M NaHCO3, pH 9.6). After washing three times in
PBS, pH 7.4, containing 0.05% Tween20, wells were blocked with
300 μl Universal Casein Diluent/Blocker (UCDB, SDT, Baesweiler,
Germany) for 2 h at room temperature. Wells were washed three
times. A 100 μl biotinylated primary antibody RabMab42-3 (appro-
priate dilution in UCDB) was added to each well and incubated for 1 h
at room temperature. After three washing steps, 100 μl Streptavidin-
PolyHRP40 conjugate (SDT, 0.2 μg/ml in UCDB) was added to each
well, followed by 1 h incubation at room temperature. After washing
six times, successful binding of the antibody was visualized by the
addition of 100 μl chromogenic substrate (es(HS)TMB, SDT) to each
well and follow-up incubation for 30 min in the dark at room
temperature. The reaction was stopped by the addition of 50 μl 2 N
H2SO4 and quantiﬁed by absorbance measurement (450 nm) in a
multilabel plate reader (VICTOR TM X5, Perkin Elmer, Vienna,
Austria).
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